Almoosa Health Company (4018) fair value: what the stock is really worth
We calculate from audited financials what Almoosa Health Company is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Almoosa Health Company for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
20‑month range 111.20 SAR – 198.68 SAR · fair‑value band 57.39 SAR – 96.12 SAR · the 117.10 SAR price screens above the 76.90 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Almoosa Health Company operates as a private healthcare provider in the Kingdom of Saudi Arabia. It stores medical items and sells medicine, cosmetics, and disposable medical items.
Show more
Almoosa Health Company operates as a private healthcare provider in the Kingdom of Saudi Arabia. It stores medical items and sells medicine, cosmetics, and disposable medical items. The company also operates specialist and rehabilitation hospitals, medical and emergency centers, pharmacies, mental health clinics, and oncology centers, as well as a college of health sciences. Its medical specialties include pain management, lymphatic massage, hyperbaric oxygen therapy, occupational therapy, speech and language disorders, personality and behavioral disorders, supportive devices and prosthetics, urology, ophthalmic surgery, general surgery, otolaryngology (ear, nose, and throat), wound care, emergency medicine, audiology, rheumatology, allergy and immunology, health education, angiography and interventional radiology, infectious diseases, chest diseases, dermatology, internal medicine, pediatrics, dentistry, nephrology, endocrinology, gastroenterology, pediatric neurology, physiotherapy, psychiatry, bone and joint surgery, psychiatric rehabilitation, therapeutic nutrition, and vascular medicine. The company was formerly known as Al Moosa Specialist Hospital and changed its name to Almoosa Health Company in February 2024. The company was incorporated in 1996 and is based in Al Mubarraz, the Kingdom of Saudi Arabia. Almoosa Health Company operates as a subsidiary of Abdulaziz bin Abdullah Almoosa Investment Company.
Stock analysis
Almoosa Health Company (4018) currently trades at 117.10 SAR, while our model-based Fair Value estimate is 76.90 SAR, implying the stock looks roughly 52.3% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 120.06 SAR per share, and 2 of the 16 models we run sit above the 117.10 SAR price.
Bear case: the Economic Profit group reads lowest at 29.23 SAR, and 14 of the 16 models stay below the price. Evidence for this calculation is high.
Scenario range: 57.39 SAR (bear) to 96.12 SAR (bull), the price of 117.10 SAR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Almoosa Health Company reported revenue of 1.4B SAR in FY2025 versus 702M SAR in FY2021, a compound +19.2%/yr. Reported net income was 200M SAR in FY2025, compounding +33.9%/yr from FY2021.
Key figures
Market cap 5.2B SAR (≈ $1.4B) · P/E ratio 26.9 · P/S ratio 3.81 · EPS (TTM) 4.35 SAR · Dividend yield 1.1% · Net margin 14.1% · Return on equity 10.0% · Return on assets (EBIT) 5.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at −34%, 4018 screens richer than that median.
Fair Value models
Bear 57.39 SARFair Value 76.90 SARBull 96.12 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (2.15 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+17.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.6%
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+36.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+35.0%
Dividend (yield on the price)1.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 14%
2025 sits 113% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 255 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−36% · Below median
Profitability
Return on equity (TTM)10% · Above median
Return on assets4% · Above median
Net margin (TTM)13% · Top 25%
Operating margin (TTM)12% · Above median
Growth and dividend
Revenue growth8% · Above median
Dividend yield (TTM)1.1% · Below median
Balance sheet
Debt / equity0.34× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)26.9× · Pricier than median
P/B0.69× · Cheapest 25%
P/S (TTM)0.95× · Cheaper than median
EV/EBITDA6.7× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 29
FUTURE (revenue growth)39· sector 27
PAST (return on equity)40· sector 31
HEALTH (low debt)83· sector 90
DIVIDEND (yield)22· sector 42
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Almoosa Health Company Fair Value". https://www.fairvalue-calculator.com/stock/4018
Frequently asked questions
Is Almoosa Health Company (4018) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 76.90 SAR versus a price of 117.10 SAR, about −34% upside (overvalued).
What is the fair value of 4018?
Our model-based fair value for Almoosa Health Company is 76.90 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 117.10 SAR.
What is the quality score of 4018?
Almoosa Health Company has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Almoosa Health Company (4018)?
Our model-based price target is the fair value of 76.90 SAR (as of Sep 13, 2026) from 16 valuation models. Cautious scenario 57.39 SAR, optimistic scenario 96.12 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Almoosa Health Company stock forecast for 2026?
Our models put fair value at 76.90 SAR, about −34% upside versus a price of 117.10 SAR (overvalued). Cautious scenario 57.39 SAR, optimistic scenario 96.12 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Almoosa Health Company (4018)?
Almoosa Health Company reported trailing-twelve-month revenue of about 1.4B SAR (latest available figure, as of Sep 13, 2026).
Does Almoosa Health Company pay a dividend?
Almoosa Health Company currently shows a dividend yield of about 1.11% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Almoosa Health Company (4018)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Almoosa Health Company it is 76.90 SAR per share (as of Sep 13, 2026), against a price of 117.10 SAR. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Almoosa Health Company stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 4018 trades above its calculated fair value: price 117.10 SAR, fair value 76.90 SAR, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4018?
No. The price is what the market pays today (117.10 SAR); the fair value is what the company's own numbers justify (76.90 SAR). For Almoosa Health Company the two are 40.20 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Almoosa Health Company worth?
The market values Almoosa Health Company at about 5.2B SAR (market capitalisation, as of Sep 13, 2026). Per share that is 117.10 SAR; our models calculate a fair value of 76.90 SAR per share.
What do the bullish and bearish scenarios say about 4018?
Our models span a range for Almoosa Health Company: cautious scenario 57.39 SAR, base 76.90 SAR, optimistic 96.12 SAR per share (as of Sep 13, 2026, price 117.10 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4018?
Almoosa Health Company trades at a price-to-earnings ratio of 26.9 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 76.90 SAR is built from several models across several years. Other multiples: P/B 0.7, P/S 0.9, EV/EBITDA 6.7.
How solid is the balance sheet of Almoosa Health Company (4018)?
Balance-sheet figures for Almoosa Health Company (as of Sep 13, 2026): return on equity 10.0%, debt of 0.34 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 4018 from its 52-week high?
Almoosa Health Company trades at 117.10 SAR, about 44% below its 52-week high of 210.60 SAR and 6% above the low of 110.00 SAR (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 76.90 SAR is for.
Which stocks are comparable to Almoosa Health Company?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Almoosa Health Company stock attractive at the current price?
The data as of Sep 13, 2026: price 117.10 SAR, calculated fair value 76.90 SAR (−34%), Quality Score 43/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4018 calculated?
We run Almoosa Health Company through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 76.90 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Almoosa Health Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Almoosa Health Company right now?
The price sits above even our optimistic bull case (96.12 SAR). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Almoosa Health Company
How large is the market capitalisation of Almoosa Health Company (4018)?
The market capitalisation of Almoosa Health Company is 5.2B SAR (≈ $1.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Almoosa Health Company (4018)?
The price-to-sales ratio of Almoosa Health Company is 3.81 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Almoosa Health Company (4018)?
Earnings per share at Almoosa Health Company are 4.35 SAR (price ÷ EPS = P/E 26.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Almoosa Health Company (4018)?
The dividend yield of Almoosa Health Company is 1.1% (payout 29.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Almoosa Health Company (4018)?
The net margin of Almoosa Health Company is 14.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Almoosa Health Company (4018)?
The return on equity (ROE) of Almoosa Health Company is 10.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Almoosa Health Company (4018)?
On an EBIT basis the return on assets of Almoosa Health Company is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Almoosa Health Company (4018)?
The operating margin of Almoosa Health Company is 11.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Almoosa Health Company (4018)?
Revenue at Almoosa Health Company is growing +7.8% versus a year earlier (3y avg +20.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Almoosa Health Company (4018)?
Earnings per share at Almoosa Health Company are growing −65.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Almoosa Health Company (4018) generate?
The free cash flow of Almoosa Health Company is −347M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Almoosa Health Company (4018) carry?
The net debt of Almoosa Health Company is 769M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Almoosa Health Company in the live analysis
One click puts Almoosa Health Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
